human serum albumin/interferon alpha2b fusion protein
Recombinant proteinexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 13, 2017 (NCT03294798)
Timeline
Indications
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06587451 | Phase 3 | Jan 1, 2025 | Sandoz |
| NCT06108050 | Phase 1 | Nov 7, 2023 | Jazz Pharmaceuticals |
| NCT03294798 | Phase 1 | Jun 13, 2017 | Capital Medical University, Fortune Rock, Fudan University, Nanjing Medical University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Fortune Rock | For profit | 1 | 1 | 1 | 2017 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Jazz Pharmaceuticals | For profit | 1 | 1 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Sandoz | For profit | 1 | 1 | 1 | 2025 |
6 organizations
Page 1 / 1